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sensitive tumours,unless it might be reasonably argued that they
might be intolerant to or anyway unsuitable for receiving T.
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Oral metronomic chemotherapy is a therapeutic option which
is particularly attractive for its ease of administration and low toxic
burden. Its mechanism of action probably involves an anti-angio-
genetic effects rather a classical antiproliferative effect like stan-
dard maximally tolerated dose-based regimens. Patients and
methods: A retrospective analysis of 22 pts with ABC was carried
out with the aim of reporting activity in terms of response rate,
tumour-related symptoms control, outcome and toxicity. All
patients had hormonal therapy-resistant metastatic disease and
had previously received two lines of chemotherapy. All patients
were treated with oral CTX 50 mg/day without interruption until
re-evaluation or progressive disease. Results: An objective
response (1 complete and 2 partial responses) was seen in 14% of
patients (95%CL 5–28%). Stable disease with a median duration of
5 months (range 3–7months) was recorded in 8 cases (36%; 95%CL
16–56%) for a TGCR of 50%. Symptoms control was achieved in
54% of cases. Toxicity was very mild and easily manageable. No
cases of extra-haematological grade 3-toxicity were observed.
Grade 3 non-febrile neutropenia were recorded in 9% of cases. Con-
clusions: Although retrospectively recorded data presented in this
study support the use of an oral metronomic chemotherapy in
patients with ABC. Relatively mild activity is however seen in heav-
ily pretreated patients without significant side-effects. Further
studies are warranted to optimise the treatment schedule and to
select patients who may benefit from such an approach.
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